Lee's Pharmaceutical Holdings Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los ingresos de Lee's Pharmaceutical Holdings aumenten en un 16.1% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	12.7%
Tasa de crecimiento de los ingresos	16.1%
Rentabilidad financiera futura	4.0%
Cobertura de analistas	Low
Última actualización	16 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?

Dec 01

Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?

Nov 18

Previsiones de crecimiento de beneficios e ingresos

SEHK:950 - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	1,461	N/A	N/A	N/A	1
12/31/2024	1,278	N/A	N/A	N/A	1
12/31/2023	1,053	17	-30	110	N/A
9/30/2023	980	5	N/A	N/A	N/A
6/30/2023	1,096	39	-133	70	N/A
3/31/2023	1,165	39	N/A	N/A	N/A
12/31/2022	1,233	51	70	284	N/A
9/30/2022	1,350	-119	N/A	N/A	N/A
6/30/2022	1,331	-140	103	317	N/A
3/31/2022	1,308	1,966	N/A	N/A	N/A
12/31/2021	1,266	1,987	-160	211	N/A
9/30/2021	1,275	2,176	N/A	N/A	N/A
6/30/2021	1,244	2,188	-65	394	N/A
3/31/2021	1,227	130	N/A	N/A	N/A
12/31/2020	1,217	129	-139	219	N/A
9/30/2020	1,199	167	N/A	N/A	N/A
6/30/2020	1,168	184	-142	179	N/A
3/31/2020	1,209	118	N/A	N/A	N/A
12/31/2019	1,219	126	39	400	N/A
9/30/2019	1,185	301	N/A	N/A	N/A
6/30/2019	1,177	331	-43	309	N/A
3/31/2019	1,139	395	N/A	N/A	N/A
12/31/2018	1,138	418	27	321	N/A
9/30/2018	1,126	243	N/A	N/A	N/A
6/30/2018	1,101	233	45	447	N/A
3/31/2018	1,064	256	N/A	N/A	N/A
12/31/2017	1,009	233	98	366	N/A
9/30/2017	981	245	N/A	N/A	N/A
6/30/2017	955	256	N/A	358	N/A
3/31/2017	930	245	N/A	N/A	N/A
12/31/2016	930	252	N/A	395	N/A
9/30/2016	911	259	N/A	N/A	N/A
6/30/2016	894	247	N/A	309	N/A
3/31/2016	917	242	N/A	N/A	N/A
12/31/2015	922	229	N/A	160	N/A
9/30/2015	976	221	N/A	N/A	N/A
6/30/2015	990	209	N/A	140	N/A
3/31/2015	979	191	N/A	N/A	N/A
12/31/2014	955	193	N/A	220	N/A
9/30/2014	874	175	N/A	N/A	N/A
6/30/2014	805	164	N/A	255	N/A
3/31/2014	755	160	N/A	N/A	N/A
12/31/2013	697	150	N/A	179	N/A
9/30/2013	658	140	N/A	N/A	N/A
6/30/2013	613	133	N/A	101	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 950 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 950 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 950 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (16.1% al año) de 950 crezcan más rápidamente que los del mercado Hong Kong (7.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 16.1% al año) de 950 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 950 sea baja dentro de 3 años (4%).

Lee's Pharmaceutical Holdings Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased to HK$1.80

Price target decreased to HK$1.80

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Price target decreased to HK$4.85

Recent updates

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)

Investor sentiment deteriorated over the past week

Non-Executive Director Simon Miles Ball has left the company

Price target decreased to HK$6.42

First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020)

Price target decreased to HK$6.92

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited Announces Sodium Phenylbutyrate Granules Obtained Approval for Drug Registration

Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019)

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019)